Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Pharmas To Fall Short Of Export Forecasts

This article was originally published in PharmAsia News

Executive Summary

India's pharmaceutical business is expected to miss 2007-2008 export growth forecasts by 23 percent. The industry blames the appreciation of the rupee for the projected failure to reach the 30 percent growth forecast. Also cited for the fall-off were pricing pressures and loss of patent protection in the United States. Others cite a U.S. recession that forces foreign companies to offer greater discounts. (Click here for more

You may also be interested in...



QUOTED. 5 August 2020. Eric Fanning.

AdvaMed’s VentConnect platform is expanding to support production of devices needed to treat COVID-19. Here’s what Eric Fanning, CEO of participating group the Aerospace Industries Association, said about the move.

Warp Speed Lives Up To Its Name: FDA Planning Late October Vaccine Advisory Committee

Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.

Ahead Of Ryoncil’s Advisory Committee, Citizen Petition Opposes Approval For Pediatric GVHD

Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.

UsernamePublicRestriction

Register

LL021103

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel